KIAA0748_5830405N20Rik Inhibitors
Chemical inhibitors of KIAA0748 can impede the protein's function through interference with upstream signaling pathways essential for its activity, particularly in the context of T-cell activation. SL327 and PD0325901, as selective inhibitors of MEK, block the activation of ERK1/2, a crucial step in T-cell receptor signaling, which is necessary for the downstream events in which KIAA0748 operates. Similarly, U0126, another MEK inhibitor, prevents the phosphorylation of ERK, thereby disrupting the MEK-ERK signaling pathway integral to KIAA0748's role. By halting ERK activation, these inhibitors effectively impede the signaling cascade that would otherwise facilitate KIAA0748's function. SP600125, which targets c-Jun N-terminal kinase (JNK), and SB203580, a p38 MAP kinase inhibitor, obstruct the broader MAPK signaling network. The inhibition of these kinases by SP600125 and SB203580 disrupts inflammatory response pathways and other signaling processes that are likely intersecting with the functional pathway of KIAA0748.
PP2, a selective Src family tyrosine kinase inhibitor, and Dasatinib, which targets Src kinases and Bcr-Abl tyrosine kinase, similarly disrupt signal transduction that is fundamental for the activation sequence involving KIAA0748. LY294002 and Wortmannin, both PI3K inhibitors, as well as Rapamycin, an mTOR inhibitor, abrogate the PI3K-AKT and mTOR signaling pathways, respectively. These pathways are instrumental in T-cell activation and the proper functioning of KIAA0748. By preventing AKT activation, LY294002 and Wortmannin eliminate critical steps that would lead to KIAA0748's participation in cellular responses. Rapamycin, on the other hand, suppresses the mTOR pathway, further inhibiting the T-cell activation process in which KIAA0748 is a component. Additionally, BAY 11-7082, by inhibiting NF-κB activation, disrupts another key signaling network related to inflammatory and immune responses, which would indirectly inhibit KIAA0748 activity. Lastly, Sunitinib, as a receptor tyrosine kinase inhibitor, interferes with various receptor-mediated signaling pathways, which may include those integral to KIAA0748's function, thereby providing a broad spectrum of inhibition across related signaling networks.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SL-327 | 305350-87-2 | sc-200685 sc-200685A | 1 mg 10 mg | $107.00 $332.00 | 7 | |
SL327 is a selective inhibitor of MAP kinase kinases (MEK), which are upstream of ERK1/2. Since KIAA0748 is involved in T-cell activation, and ERK activation is a key step in T-cell receptor signaling, inhibition of ERK1/2 phosphorylation by SL327 would prevent downstream signaling events crucial for KIAA0748 function in T-cells. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in regulating inflammatory responses. By inhibiting JNK, SP600125 could disrupt signaling pathways that include KIAA0748, thereby inhibiting its function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor, and by inhibiting p38 MAP kinase, it could prevent the phosphorylation and activation of substrates involved in the same signaling pathways as KIAA0748, resulting in functional inhibition. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. Src kinases can be involved in T-cell receptor signaling, and inhibition by PP2 can disrupt signaling cascades that are necessary for the function of KIAA0748 in T-cell activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, which would prevent the activation of AKT. Given that KIAA0748 is part of T-cell activation pathways, and PI3K-AKT signaling is crucial in this context, LY294002 can functionally inhibit the protein by halting downstream signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor and by inhibiting mTOR, it can suppress T-cell activation. Since KIAA0748 is involved in T-cell activation, rapamycin would inhibit its function by blocking a crucial signaling pathway in which KIAA0748 operates. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that prevents the activation of AKT, similar to LY294002. It would inhibit the function of KIAA0748 by disrupting the PI3K-AKT signaling pathway, which is a component of T-cell activation in which KIAA0748 is involved. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor that would prevent ERK activation. Since KIAA0748 is tied to T-cell receptor signaling, U0126 would inhibit the function of KIAA0748 by blocking the MEK-ERK signaling pathway. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 is an inhibitor of NF-κB activation. KIAA0748, involved in T-cell signaling, likely operates within the broader context of NF-κB related pathways, and its inhibition would consequently inhibit the function of KIAA0748. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase and Bcr-Abl tyrosine kinase inhibitor. By targeting Src kinases, Dasatinib would inhibit signaling pathways crucial for the function of KIAA0748 in T-cell activation. | ||||||